Patents by Inventor Philip E. Morris

Philip E. Morris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090012104
    Abstract: Described are compounds of the general formula (I), VI and (VII). Also described are pharmaceutical compositions comprising the compounds identified. The compounds and pharmaceutical compositions described are inhibitors of 5?-methylthioadenosine/S-adenosylhomocystein nucleosidase (MTAN) and/or 5?-methylthioadenosine phosphorylase (MTAP). Methods of treatment using the compounds and pharmaceutical compositions described are also provided for preventing and/or treating disease states and/or conditions by inhibiting MTAN and/or MTAP in patients.
    Type: Application
    Filed: July 26, 2005
    Publication date: January 8, 2009
    Inventors: Yarlagadda S. Babu, Vivekanand P. Kamath, Philip E. Morris, JR.
  • Patent number: 6972331
    Abstract: 4-Oxo-4,5-dihydro-3H-pyrrolo[3,2-d] pyrimidine-7-carboxylic acid methyl ester and process for preparing are provided. The process for producing the 4-oxo-4,5-dihydro-3H-pyrrole[3,2-d]pyrimidine-7-carboxylic acid methyl ester comprises condensing 3-amino-1H-pyrrole-2,4-dicarboxylic acid dimethyl ester with formamidine acetate. The 4-oxo-4,5-dihydro-3H-pyrrole[3,2-d]pyrimidine- 7-carboxylic acid methyl ester is useful as a precusor for providing 9-deaza-hypoxanthine, a key intermediate for producing certain PNP inhibitors.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: December 6, 2005
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Christopher D. Winslow, Philip E. Morris, Jr.
  • Patent number: 6946554
    Abstract: Derivatives of 9-deazaguanine of the formula I: are prepared by reacting an aldehyde or ketone of the formula II: with a dialkylaminomalonate to produce an enamine. The enamine is then reacted with a base to produce a pyrrole represented by the formula: The pyrrole is reacted with a compound represented by the formula R3OC(O)N?C(Z)NHC(O)OR3 or a derivative of carbamimidoic acid to provide a protected guanidine compound. The guanidine compound is converted to the desired deazaguanine by reaction with 1) trifluoracetic acid or 2) C1-C4 alkoxide or alkali metal or alkaline earth metal hydroxide followed by neutralization with an acid.
    Type: Grant
    Filed: June 29, 2004
    Date of Patent: September 20, 2005
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Arthur J. Elliott, David A. Walsh, Philip E. Morris
  • Publication number: 20040254181
    Abstract: Derivatives of 9-deazaguanine are prepared by reacting an aldehyde or ketone with a dialkylaminomalonate to form the corresponding enamine. The enamine is then reacted with a base to form a cyclic pyrrole. The cyclic pyrrole is reacted with an urea compound or a derivative of carbamimidoic acid to provide a protected guanidino compound. The guanidino is converted to the desired 9-deazaguanine derivative by reacting with trifluoracetic acid or with an alkoxide or hydroxide followed by neutralization with an acid.
    Type: Application
    Filed: June 29, 2004
    Publication date: December 16, 2004
    Applicant: BioCryst Pharmaceuticals, Inc.
    Inventors: Arthur J. Elliott, David A. Walsh, Philip E. Morris
  • Publication number: 20040214840
    Abstract: 4-Oxo-4,5-dihydro-3H-pyrrolo[3,2-d] pyrimidine-7-carboxylic acid methyl ester and process for preparing are provided. The 4-oxo-4,5-dihydro-3H-pyrrole[3,2-d] pyrimidine-7-carboxylic acid methyl ester is useful as a precursor for providing 9-deaza-hypoxanthine, a key intermediate for producing certain PNP inhibitors.
    Type: Application
    Filed: April 23, 2003
    Publication date: October 28, 2004
    Applicant: BIOCRYST PHARMACEUTICALS, INC.
    Inventors: Christopher D. Winslow, Philip E. Morris
  • Patent number: 6780993
    Abstract: A method for preparing 1-C-(9-deazaaden-9-yl)-1,4-imino-D-5′-deoxy-5′-methylthiorbitol) and pharmaceutically acceptable salts thereof is provided.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: August 24, 2004
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Vivekanand Kamath, Philip E. Morris, Jr.
  • Patent number: 6660719
    Abstract: T-cell inhibition proliferation in a mammalian host by administering effective amounts of 2′-deoxyguanosine and/or prodrugs thereof; and certain PNP inhibitors.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: December 9, 2003
    Assignee: BioCryst Pharmaceuticals Inc.
    Inventors: Shanta Bantia, John A. Montgomery, Philip E. Morris, Jr.
  • Publication number: 20030114466
    Abstract: T-cell inhibition proliferation in a mammalian host by administering effective amounts of 2′-deoxyguanosine and/or prodrugs thereof; and certain PNP inhibitors.
    Type: Application
    Filed: December 17, 2001
    Publication date: June 19, 2003
    Inventors: Shanta Bantia, John A. Montgomery, Philip E. Morris
  • Patent number: 6458799
    Abstract: 1-C-(9-deazaaden-9-yl)-1,4-imino-D-5′-deoxy-5′-methylthioribitol) and pharmaceutically acceptable salts thereof are useful for inhibiting MTAP and treating cancer. A method for preparing the compounds of the present invention is also provided.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: October 1, 2002
    Assignee: Biocryst Pharmaceuticals, Inc.
    Inventors: John A. Montgomery, Philip E. Morris, Jr.
  • Patent number: 6387923
    Abstract: Compounds represented by the formula: wherein A is selected from the group consisting of W is NH2 or H; and each X, Y and Z is individually selected from the group consisting of OH, H and halogen provided at least one of X and Y is H; tautomers, or pharmaceutically acceptable salts thereof; are provided. Compounds of the present invention are useful as inhibitors of PNP and of T-cell proliferation. Compounds of the present invention are useful for treating Cancer. Method for preparing the compounds of the present invention are also provided.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: May 14, 2002
    Assignee: Biocryst Pharmacueticals, Inc.
    Inventors: Philip E. Morris, Jr., John A. Montgomery, Yarlagadda S. Babu
  • Publication number: 20010053784
    Abstract: Compounds represented by the formula: 1
    Type: Application
    Filed: March 22, 2001
    Publication date: December 20, 2001
    Applicant: BIOCRYST PHARMACEUTICALS, INC
    Inventors: Philip E. Morris, John A. Montgomery, Yarlagadda S. Babu
  • Patent number: 4429615
    Abstract: A feeder for transferring ammunition from a magazine to the loading assem of an elevationally rotatable gun includes a first chute and a second chute. The first chute is pivotally mounted about the magazine. The second chute is articulated between the first chute and the loading assembly. The chutes are sized to provide an internal passage for the ammunition. An endless transfer chain can circulate along an interior path from the magazine through the chutes to drive the ammunition therethrough. This endless transfer chain returns from the interior path to the magazine along a return path. Linkage coupled to the endless transfer chain along its return path can draw it inwardly as the chutes unfold.
    Type: Grant
    Filed: April 16, 1982
    Date of Patent: February 7, 1984
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Philip E. Morris